Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.

Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De Carlo C, Qureshi MM, Ardah MT, Varghese S, Bonanni L, Borroni B, Tambasco N, Eusebi P, Rossi A, Onofrj M, Padovani A, Calabresi P, El-Agnaf O.

Mov Disord. 2011 Apr 5. doi: 10.1002/mds.23670. [Epub ahead of print]

Reply: Is cognition key in paradoxical kinesia?

Onofrj M, Bonanni L, Thomas A.

Mov Disord. 2011 Feb 1;26(2):365. doi: 10.1002/mds.23432. Epub 2010 Dec 13. No abstract available.

Eyelid retraction in dementia with Lewy bodies and Parkinson's disease.

Onofrj M, Monaco D, Bonanni L, Onofrj V, Bifolchetti S, Manzoli L, Thomas A.

J Neurol. 2011 Feb 17. [Epub ahead of print] No abstract available.

Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER).

Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P, Hill D, Anderson T, Myllyla V, Kassubek J, Steiger M, Zucconi M, Tolosa E, Poewe W, Surmann E, Whitesides J, Boroojerdi B, Chaudhuri KR; Recover Study Group.

Mov Disord. 2011 Jan;26(1):90-9. doi: 10.1002/mds.23441. Epub 2010 Nov 18.

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial.

Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M, Huyck S, Wolski K.

Lancet Neurol. 2011 Mar;10(3):221-9.

Autoscopic phenomena: case report and review of literature.

Anzellotti F, Onofrj V, Maruotti V, Ricciardi L, Franciotti R, Bonanni L, Thomas A, Onofrj M.

Behav Brain Funct. 2011 Jan 10;7(1):2.

Attention modulation regulates both motor and non-motor performance: a high-density EEG study in Parkinson's disease.

Perfetti B, Moisello C, Lanzafame S, Varanese S, Landsness EC, Onofrj M, Di Rocco A, Tononi G, Ghilardi MF.

Arch Ital Biol. 2010 Sep;148(3):279-88.

Reply: Is cognition key in paradoxical kinesia?

Onofrj M, Bonanni L, Thomas A.

Mov Disord. 2010 Dec 13. [Epub ahead of print] No abstract available.

Olanzapine enhances anxiety response to an SSRI in a woman with bipolar disorder.

Sepede G, Gambi F, Onofrj M, Di Giannantonio M, Salerno RM.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jan 15;35(1):303-4. Epub 2010 Nov 20. No abstract available.

Revisiting P300 cognitive studies for dementia diagnosis: Early dementia with Lewy bodies (DLB) and Alzheimer disease (AD).

Bonanni L, Franciotti R, Onofrj V, Anzellotti F, Mancino E, Monaco D, Gambi F, Manzoli L, Thomas A, Onofrj M.

Neurophysiol Clin. 2010 Nov-Dec;40(5-6):255-65.

Temporal evolution of oscillatory activity predicts performance in a choice-reaction time reaching task.

Perfetti B, Moisello C, Landsness EC, Kvint S, Pruski A, Onofrj M, Tononi G, Ghilardi MF.

J Neurophysiol. 2011 Jan;105(1):18-27. Epub 2010 Nov 3.

Protracted benefit from paradoxical kinesia in typical and atypical parkinsonisms.

Bonanni L, Thomas A, Anzellotti F, Monaco D, Ciccocioppo F, Varanese S, Bifolchetti S, D'Amico MC, Di Iorio A, Onofrj M.

Neurol Sci. 2010 Dec;31(6):751-6. Epub 2010 Sep 22.

Pathological gambling in Parkinson disease is reduced by amantadine.

Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M.

Ann Neurol. 2010 Sep;68(3):400-4.

Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease.

Stocchi F, Zappia M, Dall'Armi V, Kulisevsky J, Lamberti P, Obeso JA; Melevodopa Plus Carbidopa Study Group.

Mov Disord. 2010 Sep 15;25(12):1881-7.

Cohort study on somatoform disorders in Parkinson disease and dementia with Lewy bodies.

Onofrj M, Bonanni L, Manzoli L, Thomas A.

Neurology. 2010 May 18;74(20):1598-606.

Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study.

Eggert K, Squillacote D, Barone P, Dodel R, Katzenschlager R, Emre M, Lees AJ, Rascol O, Poewe W, Tolosa E, Trenkwalder C, Onofrj M, Stocchi F, Nappi G, Kostic V, Potic J, Ruzicka E, Oertel W; German Competence Network on Parkinson's Disease.

Mov Disord. 2010 May 15;25(7):896-905.

Paradoxical kinesia in parkinsonian patients surviving earthquake.

Bonanni L, Thomas A, Onofrj M.

Mov Disord. 2010 Jul 15;25(9):1302-4. No abstract available.

Severe outcome of pharyngeal-cervical-brachial pure motor axonal neuropathy.

Bonanni L, Onofrj V, Scorrano V, Onofrj M, Thomas A.

Open Neurol J. 2010 Jan 29;4:1-4.

Persistent genital arousal disorder associated with functional hyperconnectivity of an epileptic focus.

Anzellotti F, Franciotti R, Bonanni L, Tamburro G, Perrucci MG, Thomas A, Pizzella V, Romani GL, Onofrj M.

Neuroscience. 2010 Apr 28;167(1):88-96. Epub 2010 Feb 6.

Marco Onofrj, Laura Bonanni, Giovanni Cossu, Davide Manca, Fabrizio Stocchi, Astrid Thomas. Emergencies in parkinsonism: akinetic crisis, dyskinetic state, and polyneuropathy during L-Dopa gel treatment. Parkinsonism and related disorders, Parkinsonism and Related Disorders S (2009) S233–S236.

M. Onofrj, L. Bonanni, M.V. De Angelis, F. Anzellotti, F. Ciccocioppo, A. Thomas.

Long half -life and prolonged-release dopamine receptor agonists: a review of ropinirole prolonged-release studies. Parkinsonism and related Disorders, in press.

Varanese et al, Fluctuating cognition and different cognitive and behavioural profiles in Parkinsons's Disease with Dementia. Comparison with Dementia with Lewy bodies and Alzheimer's disease. Journal of Neurology Ms. No. JOON-D-09-00468R1

Astrid Thomas, Fausta Ciccocioppo, Laura Bonanni, Daniela Monaco, Stefania Bifolchetti, Francesca Anzellotti, Marco Onofrj. Manifestazioni ossessivo-compulsive nella Malattia di Parkinson. Journal of Neurodegenerative Disorders. N.4 anno 5, dicembre 2009.

L. Bonanni, MD, PhD, A. Thomas, MD, PhD, F. Ciccocioppo, MD, D. Monaco, MD, F. Anzellotti, MD, E. Mancino, M. Onofrj, MD. Mixed resting and postural tremor with overflow in orthostatism is observed in PDD/DLB patients. Submitted to Mov Disord.

L. Bonanni, MD, PhD, A. Thomas, MD, PhD, F. Anzellotti, MD, D. Monaco, MD, F. Ciccocioppo, MD, S. Varanese, MD, S. Bifolchetti, MD, M. Onofrj, MD. Paradoxical kinesia in parkinsonian patients surviving earthquake. Submitted to Mov Disord.

Astrid Thomas, MD, PhD¹*, Laura Bonanni, MD, PhD^1*, Francesco Gambi, MD PhD², Angelo Di Iorio, MD, PhD³,Marco Onofrj, MD^1* Pathological Gambling in PD abolished by Amantadine. Submitted to Annals of Neurology.

Behavioural assessment of dysexecutive syndrome in Parkinson's disease without dementia: A comparison with other clinical executive tasks. Perfetti B, Varanese S, Mercuri P, Mancino E, Saggino A, Onofrj M. Parkinsonism Relat Disord. 2009 Aug 6. [Epub ahead of print] PMID: 19665420 [PubMed]

2.7

DI fonzo A ..Onofrj M..Oostra BA,Bonifati V.GIGYF mutations are not a frequent cause of familial Parkinson Disease.Park Relat Dis 2009 Epub.

2.7

Pre-analytical factors in clinical proteomics investigations: Impact of ex vivo protein modifications for multiple sclerosis biomarker discovery. Pieragostino D, Petrucci F, Del Boccio P, Mantini D, Lugaresi A, Tiberio S, Onofrj M, Gambi D, Sacchetta P, Di Ilio C, Federici G, Urbani A. J Proteomics. 2009 Aug 8. [Epub ahead of print] PMID: 19666151 (PubMed)

-

Reale M, Iarlori C, Thomas A, Gambi D, Perfetti B, Di Nicola M, Onofrj M. Peripheral cytokines profile in Parkinson's disease. Brain Behav Immun. 2008 Jul 17. [Epub] 2009, 23:55-63

4.2

Laura Bonanni, Astrid Thomas, Pietro Tiraboschi, Bernardo Perfetti, Sara Varanese, Marco Onofrj. EEG comparison in early AD, DLB, PDD patients with a 2 years follow-up. Brain 2008 Mar; 131 (Pt 3) : 690-705. Epub 2008 Jan 17

9.0

F Anzellotti, L. Bonanni, A. Thomas, E. Iorio, M. Onofrj Delayed blink reflex in lewy bodies dementia is sensitive to cholinergic modulation. Clinical Neuropharmacology 2008; 31(4): 231-7

2.1

M. Onofrj An expert opinion on safinamide in Parkinson’s disease. Expert Opin Investig Drugs. 2008 Jul;17(7):1115-25. Review.

3.2

Invernizzi F, Varanese S, Thomas A, Carrara F, Onofrj M, Zeviani M. Two novel POLG1 mutations in a patient with progressive external ophthalmoplegia, levodopa-responsive pseudo-orthostatic tremor and parkinsonism.Neuromuscul Disord. 2008 Jun;18(6):460-4. Epub 2008 May 27.

2.3

Stocchi, F...Onofrj M., Ease-PD Monotherapy Study Investigators. Ropinerole 24 hour prolonged releaseand ropinerole immediate release in  early Parkinson Disease:a randomized double blind non inferiority study.Curr Med Res ,2008,24:2883-95

3.3

Piazzini A, Beghi E, Turner K, Ferraroni M; LICE Quality of Life Group.Health-related quality of life in epilepsy: findings obtained with a new Italian instrument. Epilepsy Behav. 2008 Jul;13(1):119-26. Epub 2008 Apr 8.

1.1

A. Antonini P. Barone, M. Onofrj, M. Zappia, A. Quattrone. COMT inhibition with tolcapone in the treatment algorithm of patients wuth Parkinson’s disease (PD) relevance for motor and non-motor feautures. Neuropsychiatr Dis Treat. 2008 Feb;4(1):1-9.

--

Thomas A, Bonanni L, Onofrj M. Symptomatic REM sleep behaviour disorder. Neurol Sci. 2007 Jan; 28 Suppl 1:S21-36

0.9

Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, Zechner S, Nagel J, Lane R.A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007 May;22(5):456-67.

2.0

Bonanni Laura, Anzellotti Francesca, Varanese Sara, Thomas Astrid, Manzoli Lamberto, Onofrj Marco Delayed blink reflex in Lewy Bodies Dementia J. Neurology Neurosurgery Psychiatry 2007 Oct; 78(10):1137-9

3.6

Perfetti B, Franciotti R, Della Penna S, Ferretti A, Caulo M, Romani GL Low-and high-frequency evoked responses following pattern reversal stimuli: A MEG study supported by fMRIconstraint Neuroimage. 2007 Apr 15;35 (3): 1152-1167; Epub 2007 Feb 7

5.6

Bonanni L.Thomas A,Varanese S., Scorrano V., Onofrj M. Botulinum toxin treatment of Lateral Axial Distonia in Parkinsonism. Movement. Disorders. 2007 Oct 31; 22(14) : 2097-103

3.3

Bonanni L, Thomas A, Scorrano V, Onofrj M. Task-specific lower lip distonia due to mantra recitation. Mov. Disord. 2007 Feb 15;22(3): 439-40

3.3

Thomas A, Bonanni L, Antonini A, Barone P, Onofrj M Dopa-responsive pseudo-orthostatic tremor in parkinsonism Mov. Dis. 2007 Movement. Disorders. 2007 Aug 15; 22(11) : 1652-6

3.3

Perfetti B, Saggino A, Ferretti A, Caulo M, Romani GL, Onofrj M. Neuron underpinning of individual differences in fluid intelligence as a function of reasoning complexity: a functional Magnetic Resonance Imaging study. Human Brain Mapping 2007 Dec 19;

4.8

Onofrj M, Thomas A, Bonanni L. New approaches to understanding hallucinations in Parkinson's disease: phenomenology and possible origins.Expert Rev Neurother. 2007 Dec;7(12):1731-50. Review.

3.0

Onofrj M, Bonanni L, Albani G, Mauro A, Bulla D, Thomas A. Visual hallucinations in Parkinson’s disease: clues to separate origins. J Neurol Sci. 2006 Oct 25;248 (1-2): 143-50 Expert Rev Neurother.

2.50

Thomas A, Bonanni L, Di Iorio A, Varanese S, Anzellotti F, D’Andreagiovanni A, Stocchi F, Onofrj M. End-of-dose deteration in non ergolinic dopamineagonist monotherapy of Parkinson’s disease. J Neurol 2006 Dec; 253 (12): 1633-9

3.0

Bonanni L, Thomas A, Onofrj M, Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium Neurology. 2006 May 9,66 (9): 1455 author reply 1455.

5. 7

Poewe W. Wolters E. EMRE m. Onofrj M. Hsu C. Tekin S. Lane R; EXPRESS Investigators Long-term benefits of rivastigmine in dementia associated with Parkinson’s disease: an active treatment extension stady. Mov Disord. 2006 Apr; 21(4): 456-61

3.3

Franciotti R. Iacono D. Della Penna S. Pizzella V. Torquati K. Onofrj M. Romani GL. Cortical rhythmus reactivity in AD, LBD and normal subjects: a quantitative MEG study. NEUROBIOL Aging. 2006 Aug; 27 (8): 1100-9. Epub 2005 Aug 1

5.6

Thomas A., M. Onofrj Akinetic crisis, acute akinesia, neuroleptic malignant-like syndrome, Parkinsonism-hyperpyrexia syndrome, and malignant syndrome are the same entity and are often indipendent of tratment withdrawal. Mov. Disord. 2005 Dec;20(12)

3.3

Onofrj M and Thomas A. Which motor symptoms worsen during cholinesterase treatment. Neurology2005 ;

5.7

Onofrj M and Thomas A. Acute Akinesia in Parkinson’s Disease. Neurology 2005, Aprile :64:1162-1169

5. 7

M Onofrj, A Thomas, F Vingerhoets, W Martin, S Gimenez, J-P Azulay Combining entacapone with levodopa/DDCI improves clinical status in Parkinson’s disease (PD) patients experiencing ‘end-of-dose wearing-off’, regardless of the dosing frequency: Results of a multicenter open-label study J Neurol Tras 2004;111(8):1053-63.

2.9

M Onofrj, D Iacono, AL Luciano, K Armellino, A Thomas, Unilateral dissociation of saccades and pursuit eye movement due to medial thalamic lesion. J Neurol Neurosurg Psychatry 2004

3.6

Stocchi F, Arnold G, Onofrj M, Kwiecinski H, Szczudlik A, Thomas A, Bonucelli U, Van Dijk A, Cattaneo C, Sala P, Fariello RG for the Safinamide Parkinson’s Study Group. Improvement of motor function in early Parkinson disease by safinamide. Neurology 2004;63:746-748

5.7

A Thomas, D Iacono, AL Luciano, K Armellino, M Onofrj. Duration of Amantadine benefit on dyskinesias of severe Parkinson’s Disease. J Neurol Neurosurg Psychatry 2004,75(1):141-3

3.6

Stocchi F., Vacca L, Berardelli A., Onofrj M., Ruggeri S., Dual dopamine agonist treatment in Parkinson’s desease J. Neurology 2003 Jul, 250 (7); 822-6

2.8

Parati EA. Pozzi S. Ottolina A. Onofrj M. Bez A. Pagano SF Neural stem cells: an overview J. Endocrinol Invest. 2004; 27 (6 Suppl):64-7. Review.

1.5

Onofrj M and Thomas A. Severe worsening of Parkinsonism in Lewy Body Dementia due to Donepezil. Neurology 2003, 25;61(10):1452.

5.7

Onofrj M and Thomas A Reply. Mirtazapine induces REM sleep behaviour disorder (RBD) In Parkinsonism. Neurology 2003; 61(8); 1161

5.7

M. Onofrj, A.L. Luciano, A. Thomas, D. Iacono; G. D’Andreamatteo, Mirtazapine induces REM sleep behaviour disorder (RBD) In Parkinsonism. Neurology 2003; 60:113-115

5.7

F. Stocchi, L. Vacca, P. Grassini, G. Battaglia, M. Onofrj, M. Valente, S. Ruggieri. Optimizing levodopa pharmacokinetics in Parkinson’s Disease: the role of COMT inhibitor. Neurol Sci 2003,24:217- 218

0.9

A Thomas, D. Iacono, AL Luciano, K. Armellino M Onofrj.Akinetic syndrome in Parkinson’s Disease. Neurol Sci 2003,24:219-220

0.9

M Onofrj, A Thomas, D Iacono, AL Luciano, A Di Iorio The effects of a cholinesterase inhibitor are prominent in patients with fluctuating cognition A part 3 study of the main mechanism of cholinesterase inhibitors in dementia . Clin Neuropharmacol 2003, 26(5):239-251

2.3

Onofrj M, Luciano AL, Iacono D, Thomas A, Stocchi F, Papola F, Adorno D, Di Mascio R. HLA typing does not predict REM Sleep Behaviour Disorder and hallucinations in Parkinson’s Disease. Mov Disord 2003 :18 :337-349.

3.3

Onofrj M, Thomas A, D’Andreamatteo G, Iacono D, Luciano AL, Di Rollo A, Di Mascio R, Ballone E, Di Iorio A. Incidence of RBD and hallucination in patients affected by
Parkinson’s Disease: 8 years follow-up. Neurol Sci 2002, 23:91-94.

0.9

Onofrj M, Thomas A, Luciano AL, Iacono D, Di Rollo A, D’Andreamatteo G, Di Iorio A. Donepezil vs Vit E in Alzheimer’s disease (AD), part 2: mild vs moderate-severe AD. Clinical Neuropharmacology 2002;45 :207-215

2.3

Onofrj M, Thomas A, Bonanni L, Iacono D, Gambi F. Leucopenia induced by low dose clozapine in Parkinson’s disease recedes shortly after drug withdrawal. Review series Psychiatry 2002;2:22-24

0.83

Onofrj M, Thomas A. One further case of pancytopenia induced by Olanzapine in a Parkinson’s Disease patient. Eur Neurology 2001;45:56-57

1.35

Thomas A, Iacono D, Bonanni L, D’Andreamatteo G, Onofrj M. Donepezil, Rivastigmine and Vitamine E in Alzheimer’s Disease: a combined P300 event related potentials-neurophysiologic test evaluation over 6 months. Clin Neuropharmacology 2001, 24(1):31-42

2.45

S.F.Pagano, S.Lucchiari, A.Bez, D.Ponti, M.Onofrj,F.Vitello, Y.Torrente, V.Di Giorgi, S.Etteri, N.Bresolin, A Colombo, M Girelli, L.Cova and E.A.Parati. The role of Interleukine-6 (IL-6) in the proliferation and differentiation of Human Neural Stem Cells. Neurosci. Res. Comm. 2001; 29 (1):1-14.

0.3

Onofrj M, Thomas A, Iacono D, D’Andreamatteo G, Paci C. Age-related changes of evoked potentials. Neurophisol Clin, 2001; 31:83-101

1.0

Onofrj M, Thomas A, Di Iorio A, Iacono D, Bonanni L Switch-over from Tolcapone to Entacapone in severe Parkinson’s Disease patients. Eur Neuro, 2001;46:11-16

1.0

Onofrj M, Thomas A, Bonanni L, Iacono D, Gambi F. Leucopenia induced by low dose clozapine in Parkinson’s Disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine. Neurol Sci 2000, 21:209-215

0.9

Onofrj M, Paci C, D’Andreamatteo G, Toma L. Olanzapine in severe Gilles della Tourette Syndrome (GTS): cross over vs pimozide. J. Neurol 247:443-446;2000

3.0

Pagano F, Impagnatiello F, Girelli M, Cova L, Grioni E, Onofrj M, Cavallaro M, Etteri S, VitelloF, Solero CL, Giombini S, Parati EA. Isolation and characterization of neural stem cells from the adult human olfactory bulb. Stem Cells 18(4):295-300; 2000

7.9

Onofrj M and Thomas A. Acetazolamide Responsive Periodic Ataxia induced by Amiodarone. Mov. Disord. March 14(2):379-381,1999

3.3

Thomas A and Onofrj M. Sporadic Acetazolamide Responsive Episodic Ataxia. Mov. Disord. 14:6:10551056;1999

3.3

Onofrj M., Fulgente T., Malatesta G., Locatelli T. Focal abnormalities of P3 ERPs unveiled in patients with cortical lesions and primary progressive aphasia by average reference recordings. Brain Topography, 6(4): 311-322, 1994 (IF dal 1999 - 1.50)

1.4

A. Verotti, S. Domizio, D. Melchionda, M. Guerra, T. Mucedola, M. Onofrj, F. Chiarelli, G. Sabatino. Stormy Onset in benign childhood epilepsy with occipital paroxysmal discharges. Child’s Nervous System 1999

1.3

Onofrj M, Thomas A, Paci C, D’Andreamatteo G, Toma L, Rotilio D. Optic Neuritis with residual tunnel vision in perchloroethilene toxicity. Eur Neuro1999, 51-53

1.0

Melchionda D, Verrotti A, Chiarelli F, Domizio S, Sabatino G, Mucedola T, D’Andreamatteo G, Toma L, Di Iorio A, Onofrj M. Headache in children with centro-temporal spikes. Neurophysiol Clin. 1999; 90-100

1.0

Onofrj M, Thomas A, Paci C, Rotilio D. Optic Neuritis with residual Tunnel Vision in perchloroethilene toxicity. J. Toxicol. Clin. Tox.icol 36 (6) 603-607, 1998

2.0

Onofrj M, Thomas A, Paci C. Reversible Parkinsonism induced by prolonged treatment with Valproate. J Neurol, 245:794-796,1998

3.0

De Feo MR, Mercarelli O, Marciani MG, Striano S, Tata MR, D’Alesandro PD, Cerone G, Ortenzi A, Onofrj M. Vigabatrin monotherapy in newly diagnosed partieal epilepsy: an open multicentre Italian pilot study. Med Sci Res , 283-284, 1998

0.3

Melchionda D, Verrotti A, Chiarelli F, Domizio S, Sabatino G, Mucedola T, D’Andreamatteo G, Toma L, Di Iorio A, Onofrj M. Headache in children with centro-temporal spikes. Neurophysiol Clin. 1999; 90-100

1.0

Onofrj M, Thomas A, Paci C, D’Andreamatteo G. Gabapentin in orthostatic Tremor: results of a double blind cross-over with placebo in 4 patients. Neurology 51 Sep Vol. 51: 880-882, 1998

5.7

Onofrj M, Thomas A, Paci C, Rotilio D. Optic Neuritis with residual Tunnel Vision in perchloroethilene toxicity. J. Toxicol. Clin. Tox.icol 36 (6) 603-607, 1998

2.0

Onofrj M, Paci C, Thomas A. Sudden appearence of invalidanting dyskinesia-dystonia and off-fluctuations after the introduction of L-Dopa in two dopamimetic drugs naive stage IV Parkinson’s Disease patients. J Neurol Neurosurg Psychiat Vol 65 n. 4 pag 605-606, 1998

3.6

Caraceni A, Martini C., Spatti G., Thomas A., Onofrj M. Recovering optic Neuritis during systemic cisplatin and carboplatin chemiotherapy. Acta Neurol Scand.1997, 96: 260-261

1.8

Onofrj M., Thomas A., Paci C, Scesi M., Tombari R. Event related potentiales (ERPs) recorded in patients with locked-in syndrome (LIS). J Neurol Neurosurg Psychiatry 1997, 63: 759-764

3.6

Sabatino G, Verrotti LA, Ramenghi S, Domizio S, Melchionda D, Fulgente T, Paci C, D’Andreamatteo G,Thomas A, Onofrj M. Newborns with hyperbilirubinemia: usefulness of brain-stem auditory response evaluation. Neurophysiologie Clinique, 26:363-368,1996

1.0

Onofrj M, Melchionda D, Thomas A, Fulgente T. Reappearance of event related p3 potential in locked-in syndrome. Cogn. Brain Research, 4:95-97, 1996

2.3

Sabatino G, Verrotti LA, Ramenghi S, Domizio S, Melchionda D, Fulgente T, Paci C, D’Andreamatteo G,Thomas A, Onofrj M. Newborns with hyperbilirubinemia: usefulness of brain-stem auditory response evaluation. Neurophysiologie Clinique, 26:363-368,1996

1.0

Onofrj M, Thomas A, Melchionda D. Brain Water Intoxication and CT scan Hypolucencies in Ovarian Hyperstimulion SyndromeComplicating Gametes Intra- Fallopian Transfer (GIFT) and Tubaric Pregnancy. J.Neurol.Neurosur. Psychiatry 60:233- 234, 1996

3.6

Onofrj M, Fulgente T, Thomas A, Gambi D. Delayed and pseudodelayed VEPs in opticneuritis (ON) compared with long time echo STIR MRI of optic nerves. Electroenceph. Clin. Neurophysiol. 100: 275-286, 1996

2.47

Gambi D., Fulgente T., Melchionda D., Onofrj M. Evoked Potential (EP) Alterations in Experimental Allergic Encephalomyelitis (EAE): Early Delays and Latency Reductions Without Plaques. Ital. J. Neurol. Sci., 23-34, 1996

0.9

Onofrj M., Fulgente T., Malatesta G., Thomas A., Locatelli T., Comi G. P300 asymmetries in focal brain lesions are reference dependent. Electroenceph. Clin. Neurophysiol., 94: 432-439, 1995

2.27

Fulgente T, Thomas A, Lobefalo L, Mastropasqua L, Gallenga PE, Gambi D, Onofrj M. Are VEP abnormalities in optic neuritis (ON) Dependent on plaque size? A reappraisal of the physiopathology of ON based on improved MRI and multiple-lead recordings. Ital. J. Neurol. Sci., 43-54, 1995

0.9

Onofrj M., Tartaro A., Thomas A., Gambi D., Fulgente, T., Delli Pizzi C., Bonomo L. Long time echo STIR sequence Magnetic Resonance Imaging of optic nerves in opticneuritis. Neuroradiology, 1996, 38:66-69

1.6

Tartaro A, Onofrj M, Delli Pizzi C, Bonomo L, Thomas A, Fulgente T, Gambi D. Long time echo STIR sequence magnetic resonance imaging of optic nerves in Optic neuritis.Ital. J. Neurol. Sci., 35-42, 1995

0.9

Onofrj M., Fulgente T., Thomas A., Peresson M., Lopez L., Locatelli T., Martinelli V., Comi G. Visual Evoked Potentials generator model derived from different spatial frequency stimuli of visual field regions and magnetic resonance imaging coordinates of V1, V2, V3 areas in man. Int. J. Neuroscience, 83: 213-239; 1995 (rivista pubblicata dal 1982 al 1995)

0.8

Onofrj M, Fulgente T., Melchionda D., Marchionni A., Tomasello F., Salpietro FM., Alafaci C., De Sanctis E., Pennisi G., Ventura F., Morganti A. L-Acetylcarnitine as a new therapeutic apphroach for peripheral neuropaties with pain. Int. J. Clin. Pharm. Res., XV (1):17-22, 1995

0. 6

Onofrj M., Curatola L., Valentini G.L., Antonelli M., Thomas A., Fulgente T. Non dominant dorsal-prefrontal activation during chess problem solution evidenced by single photon emission computerized tomography (SPECT). Neuroscience Letters,198: 169-172, 1995

2.1

Onofrj M., Fulgente T., Thomas A., Peresson M., Locatelli T., Martinelli V., Comi G. Source model and scalp topography of pattern reversal Visual Evoked Potentials (VEPs) to altitudinal stimuli suggested that infoldings of calcarine fissure are not part of VEP generators. Brain Topography, 3:217-231,1995 (IF dal 1999 - 1.50)

1.4

Onofrj M., Fulgente T., Thomas A. Event related potentials recorded in dorsal simultanagnosia. Cognitive Brain Research, 3:25-32, 1995

2.3

Onofrj M., Fulgente T., Malatesta G., Ferracci F., Thomas A., Curatola L., Bollettini F., Ragno M. ½e abnormality of N30 somatosensory evoked potential in idiopathicParkinson's disease is unrelated to disease stage or clinical scores and insensitive to dopamine manipulations. Movement Disorders, Vol. 10, No 1 pp71-80, 1995

3.3

Tartaro A., Onofrj M., Thomas A., Fulgente T., Delli Pizzi C., Bonomo L. Long Time Echo STIR Sequence Magnetic Resonance Imaging of Optic Nerves in Optic Neuritis. Eur. J. Radiol., 19:155-163, 1995

1.3

Onofrj M., Ferracci F., Fulgente T., Malatesta G., Ghilardi M.F. Effects of drug manipulations on anterior components of somatosensory evoked potentials in parkinsonian animal model.Drugs Exptl. Clin. Res., Vol.20 (1):29-36, 1994

1.0

Onofrj M., Ferracci F., Fulgente T., Malatesta G., Ghilardi M.F. Effects of drug manipulations on anterior components of somatosensory evoked potentials in parkinsonian animal model.Drugs Exptl. Clin. Res., Vol.20 (1):29-36, 1994

1.3

Onofrj M., Fulgente T., Malatesta G., Ferracci F. Visual Evoked Potentials (VEPs) to altitudinal stimuli: effects of stimulus manipulations on VEP scalp topography. Clin. Vision Sci., Vol.8 (6):529-544, 1993

1.3

Onofrj M., Fulgente T., Gambi D., Macchi G. Early MRI findings in Creutzfeldt-Jakob disease. Jour. Neurol., 240:423-426, 1993

3.0

Onofrj M., Gambi D., Bazzano S., Colamartino P., Fulgente T., Malatesta G., Ferracci F. Evoked Potentials (EPs) in Experimental Allergic Encephalomylitis: a study of EP modifications during the course of a controlled disease. Electromyogr. Clin. Neurophysiol., 32:125-135, 1992

0.0

Onofrj M., Curatola L., Ferracci F., Fulgente T. Narcolepsy associated with primary temporal lobe B-cells lymphoma in a HLA DR2 negative subject. Jour. Neurol. Neurosurg. Psychiat., 55:852- 853, 1992

3.6

Onofrj M., Fulgente T., Nobilio D., Malatesta G., Bazzano S., Colamartino P., Gambi D P3 recordings in patients with bilateral temporal lobe lesions. Neurology, 42 (9):1762-
1767, 1992.

5.7

Onofrj M., Gambi D., Bazzano S., Colamartino P., Fulgente T., Malatesta G., Ferracci F. Evoked Potentials (EPs) in Experimental Allergic Encephalomylitis: a study of EP modifications during the course of a controlled disease. Electromyogr. Clin. Neurophysiol., 32:125-135, 1992

0.0

Caraceni T., Musicco M., ..... Onofrj M., et al. A multicenter italian randomised study on early treatment of Parkinson disease: comparison of l-dopa, l-deprenyl and dopaminoagonists. Study design and short term results. Ital.J.Neurol.Sci.,13:735-739, 1992.

0.9

Onofrj M., Curatola L., Malatesta G., Colamartino P., Bazzano S., Fulgente T., Ferracci F. Delayed P3 Event Related Potentials (ERPs) in Thalamic Hemorrhage. Electroenceph. Clin. Neurophysiol., 83:52-61, 1992.

2.7

Onofrj M., Curatola L., Malatesta G. Bazzano S., Colamartino P., Fulgente T. Reduction of P3 latency during outcome from post-traumatic amnesia. Acta Neurol. Scand., 83: 273-279, 1991.

1.8

Uncini A., Gallucci M., Lugaresi A., Porrini AM., Onofrj M., Gambi D. CNS involvement in chronic infiammatory polyneuropathy. An electrophysiological and MRI study. Electromyogr. Clin. Neurophysiol., 31: 365-371, 1991.

0.0

Onofrj M., Gambi D., Del Re ML., Fulgente T., Bazzano S., Colamartino P., Malatesta G. Mapping of event related potentials to auditory and visual oddball paradigms in patients affected by different forms of dementia. Eur. Neurol., 31: 259-269, 1991.

1.0

Uncini A., Gallucci M., Lugaresi A., Porrini AM., Onofrj M., Gambi D. CNS involvement in chronic infiammatory polyneuropathy. An electrophysiological and MRI study. Electromyogr. Clin. Neurophysiol., 31: 365-371, 1991.

0.0

Onofrj M., Gambi D., Del Re ML., Fulgente T., Bazzano S., Colamartino P., Malatesta G. Mapping of event related potentials to auditory and visual oddball paradigms in patients affected by different forms of dementia. Eur. Neurol., 31: 259-269, 1991.

1.0

Bodis-Wollner I., Chung E., Ghilardi MF., Glover A., Onofrj M., Pasik P., Samson Y. Acetyl-levo-carnitine protects against MPTP-induced parkinsonism in primates. J. Neural Trasm., 3: 63-72, 1991.

2.9

Onofrj M., Fulgente T., Nobilio D., Bazzano S., Colamartino P. Mapping of event related potentials to auditory and visual oddball paradigms in controls. Eur. Neurol., 31: 220-228, 1991.

1.0

Onofrj M., Gambi D., Fulgente T., Bazzano S., Colamartino P. Persistence of P3 component in severe Amnestic Syndrome. Electroenceph. Clin. Neurophysiol., 78: 480-484, 1991.

2.3

Visual "cognitive" Evoked Potentials in the behaving monkeys. Electroenceph. Clin. Neurophysiol. 80(1): 65-72, 1991.

2.3

Onofrj M., Bazzano S., Malatesta G., Fulgente T. Mapped distribution of pattern reversal VEPs to central field and lateral half-field stimuli of different spatial frequencies. Electroenceph. Clin. Neurophysiol., 80: 167-180, 1991.

2.3

Onofrj M., Fulgente T., Nobilio D., Bazzano S., Colamartino P. Mapping of event related potentials to auditory and visual oddball paradigms in controls. Eur. Neurol., 31: 220-228, 1991.

1.0

Ghilardi MF., Sartucci F., Brannan JR., Onofrj M., Bodis-Wollner I, Mylin L., Stoch R. N70 and P300 can be independently affected in multiple sclerosis. Electroenceph. Clin. Neurophysiol., 80: 1-7,1991.

2.3

Onofrj M., Ghilardi MF., Basciani M., Martinez-Tica J., Glover A. Attenuation of the early anterior negativity of median nerve somatosensory evoked potentials in the MPTP-treated monkeys. Neurophysiol. Clin., 20: 283-293, 1990.

1.0

Onofrj M., Basciani M., Fulgente T., Bazzano S., Malatesta G., Curatola L. Maps of somatosensory evoked potentials (SEPs) to mechanical (tapping) stimuli: comparison with P14, N20, P22, N30 of electrically elicited SEPs. Electroenceph. Clin. Neurophysiol., 77: 314-319, 1990.

2.3

Nobilio D., Faricelli A., Colangelo U., Del Re ML., Bazzano S., Onofrj M., Gambi D. The effect of Levo-Acetyl-carnitine on P300 potentials. Curr. Therap. Res., 47, 2: 267-277, 1990.

0.3

Onofrj M., Bazzano S., Malatesta G., Gambi D. Patophysiology of delayed evoked potentials in multiple sclerosis. Funct. Neurol., V, 4: 301-319, 1990.

0.6

Fulgente T., Onofrj M., Del Re ML., Ferracci F., Bazzano S., Ghilardi MF., Malatesta G. Laevo-Acetyl Carnitine (Nicetile) treatment of senile depression. Clin. Trial J., 27, 3: 155-163, 1990.

0.28

Delacour J., Bassant MH., Onofrj M., Santucci V., Kleinlogel H. Electrophysiological models for the study of cognition enhancers. Pharmacopsychiat., 2, 23: 90-93, 1990.

2.8

Onofrj M., Ghilardi MF., Basciani M., Martinez-Tica J., Glover A. Attenuation of the early anterior negativity of median nerve somatosensory evoked potentials in the MPTP-treated monkeys. Neurophysiol. Clin., 20: 283-293, 1990.

1.0

Uncini A., Basciani M., Di Muzio A., Antonini D., Onofrj M. Methyl bromide myoclonus: an neurophysiological study of myoclonus due to Metylbromide intoxication. Acta Neurol. Scand., 81: 159-164, 1990.

1.8

Onofrj M., Ghilardi MF. MPTP induced Parkinsonian syndrome: long term follow-up and neurophysiological study. It. J. Neurol. Sci., 11: 445-458, 1990.

0.9

Uncini A., Onofrj M., Basciani M., Cutarella R., Gambi D. Orthostatic tremor: Report of two cases and an electrophysiological study. Acta Neurol. Scand., 79: 119-122, 1989.

1.8

Gambi D., Onofrj M., Calvani M., Faricelli A., Del Re ML., Bazzano S., Cutarella R., Fulgente T., Colangelo U. Neurophysiological studies of Acetyl L Carnitine. Administration in man. Drugs Exptl. Clin. Res., 15: 960-972, 1989.

1.0

Onofrj M., Gambi D., Malatesta G., Ferracci F., Fulgente T. Electrophysiological techniques in the assessment of aging brain: lacunar state and differential diagnosis. Eur. Neurol., 462: 1-5, 1989.

1.0

Basciani M., Onofrj M. A simple system for vibrotactile tapping stimulation in neurophysiological investigations. Med. Sci. Res., 16: 1237-1238, 1988.

0.3

Uncini A., Treviso M., Basciani M., Onofrj M., Gambi D. Associated Central and peripheral demyelination: an electrophysiological study. J. Neurol., 235: 238-240, 1988.

3.0

Ghilardi MF., Bodis-Wollner I., Onofrj M., Marx MS., Glover A. Spatial frequency-dependent abnormalities of the pattern electroretinogram and visual evoked potentials in a parkinsonian monkey model. Brain, III: 131-149, 1988.

7.6

Ghilardi MF., Chung E., Bodis-Wollner I., Dvorzniak M., Glover A., Onofrj M. Systemic1-Methyl, 4-Phenyl, 1-2-3-6 tetrahydropyridine (MPTP) administration decreases retinal dopamine content in primates. Life Sci., 43: 255-262, 1988.

2.4

Onofrj M., Bodis-Wollner I., Calvani M. Effect of L-Acetyl carnitine HCl on rat steady state VEPs. Comparision with L-Carnitine. Drugs Exptl. Clin. Res., 13: 5-13 1987.

1.0

Onofrj M., Ghilardi MF., Faricelli A., Bodis-Wollner I., Calvani M. Effect of Levo-Acetyl carnitine on P300 like potentials of the normal monkey. Drugs Exptl. Clin. Res., 13: 5-13, 1987.

1.0

Ghilardi MF., Marx M.S., Onofrj M., Glover A., Bodis-Wollner I. Scalp distribution of pattern visual evoked potentials in normal and hemianopic monkeys. Physiol. Behav., 41: 297-302, 1987.

2.4

Onofrj M., Basciani., Censoni AG., Gambi D. Serial recording of VEPs to different stimuli in multiple sclerosis patients. It. J. Neurol. Sci., 6: 113-119, 1987.

0.9

Pinto F., Onofrj M., Pola P., Tempesta E, Torrioli M.G. Fetal Addiction to methadone: postnatal abstinence syndrome and development of visual evoked potentials. Drug and Alcohol Dependence, 18: 1-10, 1986.

3.2

Scerrati M., Onofrj M., Pacifici L., Pola P., Ramacci MT., Rossi GF. Electrocerebral and behavioural analysis of systemic kainic acid- induced epilepsy in the rat. Drugs Exptl. Clin. Res., 2: 671-680, 1986.

1.0

Onofrj M., Ghilardi MF., Basciani M., Gambi D. Visual Evoked Potentials in Parkinsonism and dopamine blockade reveal a stimulus-dependent dopamine function in humans. J. Neurol.Neurosurg. Psychiat., 49: 1150-1159, 1986.

3.6

Onofrj M., Basciani M., Treviso M., Uncini A. Recovery of VEP delay in patients with vitamin B12 deficiency. It. J. Neurol. Sci., 6: 491-493, 1985.

0.9

Onofrj M., Harnoys C., Bodis-Wollner I. The hemispheric distribution of the transient rat VEP: a comparison of flash and pattern stimulation. Exp. Brain Res., 59: 427-433, 1985.

2.0

Onofrj M., Falsini B., D'Annunzio V., Basciani M. Treviso M. Pattern electroretinograms recorded simultaneously with VEPs by means of an inexpensive electrode. I.R.C.S. Med. Sci., 13: 227-228, 1985.

0.2

Harnoys C., Bodis-Wollner I., Onofrj M. The effect of contrast and spatial frequency on the visual evoked potentials of the hooded rat. Exp. Brain Res., 57: 1-8, 1984.

2.0

Onofrj M., Bodis-Wollner I., Pola P., Calvani M. Central cholinergic effect of L-Acetyl Carnitine. Drugs Exp. Clin. Res., 9: 161-168, 1983.

0.58

Scerrati M., Onofrj M., Pola P. Effects of spinal cord stimulation on spasticity: H-reflex study. Appl. Neurophysiol., 45: 62-67, 1982.

0.81

Onofrj M., Bodis-Wollner I., Mylin L. VEP diagnosis of field defects in patient with chiasmatic and retrochiasmatic lesions. J. Neurol. Neurosurg. Psychiat., 45: 294-302, 1982.

3.6

Onofrj M., Bodis-Wollner I. Dopaminergic deficency causes delayed visual evoked potentials in rats. Ann. Neurol., 11: 484-490, 1982.

8.1

Onofrj M., Bodis-Wollner I., Bobak P. Pattern visual Evoked Potentials in the rats. Physiol. Behav., 28: 227-230, 1982.

2.4

Pinto F., Onofrj M., Mancinelli R., Garzetti GG., Masini L. Bellati U. A follow-up electrophysiological study of rats with poor intrauterine fetal growth: the development of visual evoked responses (VERs) Experientia, 37: 724-725, 1981.

1.86

Onofrj M., Bodis-Wollner I., Mylin LH. Visual Evoked Potential latencies in papilledema and hydrocephalus. Neuro- Ophthalmology, 2, 2: 85-92, 1981.

1.35

Onofrj M., Pinto F., Mancinelli R., Pola P. Frequency and luminance sensitivity of visual evoked responses in developing rats. Physiol. Behav., 25: 299-303, 1980.

2.4

Gambi D., Rossini PM., Onofrj M., Marchionno L. Visual Evoked Cortical Potentials by television presentation of different patterned stimuli to patients with multiple sclerosis. It. J. Neurol. Sci., 1, 2: 101-106, 1980.

0.12